Hudak calls on province to fund ailing boy's treatment St. Catharines Standard, Canada - Nov 21, 2008 However, he noted there are only six cases of Hunter syndrome in Ontario and Andrew has shown some improvement since his Elaprase treatment began.
Things looking up a bit for Andrew Welland Tribune, Canada - Nov 7, 2008 The drug Elaprase, approved by Health Canada in June, can't cure Hunter syndrome, but can improve a person's quality of life. The Lanese family has been ...
A very special evening for Andrew Lanese Niagarathisweek.com, Canada - Nov 21, 2008 Although there is no cure for Hunter Syndrome, there is a treatment called Elaprase which improves the symptoms of Hunter's. Andrew's father Nick and mother ...
UPDATE: Shire Aims To Grow Sales In Mid-Teens Range By 2015 EasyBourse.com, France - Nov 18, 2008 Shire currently markets Replagal for Fabry's disease and Elaprase for Hunter syndrome, an inherited condition characterized by the gradual deterioration of ...SHPGY
Source: Google News
Recent News and Articles on the Keywords: hunter + elaprase + syndrome Related to the article below (Last Update: 8/7/2008)
Canada should follow the US example on 'orphan' diseases Globe and Mail, Canada - Jul 17, 2008 For example, Hunter syndrome (also known as MPS II), an enzyme disorder that affects only about 40 people nationwide, can be treated effectively with a drug ...
Source: Google News
The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome) - AR Garcia, J Pan, JC Lamsa, J Muenzer - Journal of Inherited Metabolic Disease, 2007 - Springer ... of mucopolysaccharidosis II (Huntersyndrome) AR Garcia & J. Pan & JC Lamsa & J.
Muenzer ... Mucopolysaccharidosis II (Huntersyndrome): OMIM 309900. ...
[CITATION] FDA OKs 1st Drug for Hunter Syndrome M Hitti, B Warning
[CITATION] US FDA Clears Shire Drug for Hunter Syndrome CME Tracker
[CITATION] International Approvals: Nexavar, Elaprase, Aranesp Y Waknine
[CITATION] International Approvals: Prexige, Elaprase, Micera Y Waknine
[CITATION] International Approvals: Tysabri, Elaprase, Invega Y Waknine
International Approvals: Mirena, Champix, Elaprase Y Waknine - medscape.com ... Idursulfase Intravenous Infusion (Elaprase) for HunterSyndrome in EU On January
11, the European Commission approved idursulfase intravenous infusion (Elaprase...
IDURSULFASE IN HUNTER SYNDROME TREATMENT - G Zareba - Drugs of Today, 2007 - journals.prous.com ... Enzyme replacement therapy with Elaprase (idursulfase, a recently approved
orphan product) is the first treatment for Huntersyndrome. ... -
[CITATION] FDA Approvals: Xolegel, Keppra, and Elaprase CME/CE T Month, P Months
Hunter syndrome: to treat or not to treat J Muenzer, AM Martins - Acta Paediatrica, 2008 - Blackwell Synergy ... Enzyme replacement therapy (ERT) with idursulfase (Elaprase ? ; Shire HGT, Danderyd,
Sweden) for treating patients with Huntersyndrome has recently been ...
Source: Google Scholar
Elaprase, the first treatment for Hunter syndrome
The FDA ( Food and Drug Administration ) has approved Elaprase ( Idursulfase ), the first product for the treatment of Hunter syndrome ( Mucopolysaccharidosis II, or MPS II ), a rare inherited disease which can lead to premature death.
Hunter syndrome, which usually becomes apparent in children one to three years of age, is a disease in which the person's body is defective in producing the chemical iduronate-2-sulfatase, which is needed to adequately breakdown complex sugars produced in the body.
Symptoms include growth delay, joint stiffness, and coarsening of facial features.
In severe cases, patients experience respiratory and cardiac problems, enlargement of the liver and spleen, neurological deficits, and death.
Elaprase was designated as an orphan product by FDA.
Hunter syndrome is diagnosed in approximately one out of 65,000 to 132,000 births.
Elaprase was approved after a randomized, double-blind, placebo-controlled study of 96 patients with Hunter syndrome showed that the treated participants had an improved capacity to walk.
At the end of the 53–week trial, patients who received Elaprase infusions experienced on average a 38-yard greater increase in the distance walked in six minutes compared to the patients on placebo.
The most serious adverse events reported during the trial were hypersensitivity reactions to Elaprase that could be life-threatening. They included respiratory distress, drop in blood pressure, and seizure. Other frequent, but less serious adverse events included fever, headache and joint pain.
Because of the potential for severe hypersensitivity reactions, appropriate medical support should be readily available when Elaprase is administered.
